Our staff has deemed the following public research links as significant and/or new findings by the global research community in the search for a cure for paralysis. You can search the database by category, keyword, name, and/or date. Keep abreast of cure research breakthroughs by signing up for our research newsletter.

Register To Receive Updates

Click the button below to register to receive regular updates from MCPF.



To search articles by keyword or date, enter your search criteria in the box and click the Search button.

All Articles
1 2 3 4 5 6 7 8 9 10 ...
 

Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 SCiStar Study posted Wednesday, 23 August 2017
Source: Asterias Biotherapeutics FREMONT, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1...
Category: Clinical Trials


NEW SPINAL CORD INJURY REPAIR COMPANY LAUNCHED posted Friday, 18 August 2017
Elizabeth Hofheinz, M.P.H., M.Ed. • Fri, August 18th, 2017 Print this article Based on an innovative technology from Yale University which has shown promise to grow nerve fibers naturally and restore all facets of nerve function, a new company, ReNetX Bio (formerly known as Axerion Therapeutics), has been launched. ReNetX Bio is focused on providing physicians with a novel treatment for...
Category: General


Nerve fibers regenerated with molecular mix posted Thursday, 17 August 2017
By Ana Sandoiu Damage to a neuron's axon, or nerve fiber - the 'long tail' that sends signals from the cell body - is a key element of spinal cord injury. Scientists may have found a way to regrow axons - a crucial part of a neuron also known as a nerve fiber - after injury. The findings may help patients with spinal cord injury, stroke, or other neurodegenerative conditions recover their motor skills. A team of researchers at Boston Children's Hospital in Massachusetts have developed a "recipe" for a mixture of molecules and tested its therapeutic potential in mice with spinal cord injury (SCI) or stroke...
Category: Pharmaceutical


Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial posted Thursday, 10 August 2017
By GlobeNewswire, August 09, 2017, 07:00:00 AM Enrollment for entire SCiStar study expected to be completed by end-2017 FREMONT, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the first patient in the fifth and final cohort in the company's ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in motor complete cervical spinal cord injury (SCI). This cohort will dose between five and eight patients with AIS-B (motor complete, sensory incomplete) cervical spinal cord injuries with 20 million AST-OPC1 cells...
Category: Clinical Trials


Nipro closing in on stem cell cure for spinal cord injuries posted Saturday, 05 August 2017
OSAKA -- Medical equipment maker Nipro could commercialize next year a stem-cell-based treatment seen allowing people with spinal cord injuries to walk again. The Osaka-based company has carried out joint research with Sapporo Medical University since 2014. They recently found success in trials where stem cells harvested from bone marrow and increased are returned to the body, where they concentrate in injured areas of the spinal cord and regenerate tissue...
Category: Clinical Trials


Surgery can prompt sensory nerves to ‘sprout’ fresh connections to spinal cord posted Wednesday, 02 August 2017
Jamie Seidel, News Corp Australia Network THE quest to repair spinal cord injuries is a medical holy grail. Now, we’re beginning to understand how it could be done. And the fix may already be in our own bodies. A study by Kings College London examined a new surgery technique capable of reconnecting complex sensory neurons to the spinal cord. Specifically, the Frontiers in Neurology study looked at how the spinal cord of a rat went about completing the repair itself...
Category: General


Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium posted Monday, 10 July 2017
CAMBRIDGE, MA, USA I July 10, 2017 I Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment, today announced the presentation of data from its SRK-015 antibody program, in collaboration...
Category: Clinical Trials


Researchers Provide the First Evidence That a New Kind of Paralysis Treatment Is Effective posted Monday, 26 June 2017
A new study has revealed the potential for cortical targets to improve motor function in those struggling with paralysis. Cortical targets are relatively unexplored territory for treatment, so building off this research could lead to even more exciting discoveries.
Category: Other Research


Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1 posted Tuesday, 13 June 2017
FREMONT, Calif., June 13, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) patients..
Category: Clinical Trials


Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury posted Wednesday, 12 April 2017
GERMANTOWN, Md., April 12, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced that a new cohort of four patients will be added to its ongoing Phase 1 human clinical trial evaluating the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair...
Category: Clinical Trials

1 2 3 4 5 6 7 8 9 10 ...
Morton Cure Paralysis Fund - Minnesota
5021 Vernon Ave., Suite 145
Minneapolis, MN 55436
(612) 904-1420
info@mcpf.org
Morton Cure Paralysis Fund - Arizona
4939 W. Ray Rd., Suite 4190
Chandler, AZ 85226
(612) 904-1420
info@mcpf.org